IGHE and angioedema: Despite ongoing treatment with current standard of care, complete control of CSU and angioedema remains hard to achieve in some patients and additional treatment options are needed.14, 15, 16 Ligelizumab is a next generation, high affinity, 97% humanized, monoclonal anti-IgE antibody which results in rapid, strong, and sustained urticaria control,17, 18, 19, 20, 21, 22 as demonstrated in the Phase 2b core study (ClinicalTrials.gov number: NCT02477332)18 followed by a one-year Phase 2b extension study (ClinicalTrials.gov number: NCT02649218).23